Arikace amikacin: Completed Phase II enrollment

Insmed completed enrollment of 90 patients in the double-blind, placebo-controlled, North American Phase II TARGET-NTM trial evaluating once-daily 560 mg Arikace administered with the eFlow Nebulizer System from Pari GmbH (Starnberg, Germany) for 84 days. Following the double-blind portion, patients may enroll in an 84-day, open-label portion. ...